Corti launched a Global Healthcare AI Startup Program.
The Story
This initiative comes as regulatory pressure increases across Europe and the US.
Why It Matters
The EU AI Act is coming in August 2026. This Corti program highlights that even new AI solutions must prioritize regulatory compliance from day one. For CROs and generic pharma, this means evaluating any AI tool not just on its promise, but on its built-in adherence to GDPR and future AI regulations. Don't invest in tools that will become liabilities.
What To Do About It
Before adopting any new AI tool, demand a clear audit trail for data handling and model decisions. Ask vendors how their solution will integrate with your existing data sovereignty requirements and prepare for the EU AI Act. If they cannot answer clearly, walk away.
Sources
Related Signals
Novo Nordisk salvaged a scrapped Parkinson’s cell therapy project by partnering with an AI biotech.
12 May 2026
Taimei Technology and C&R Research are partnering to build AI-powered clinical trial innovation.
11 May 2026
Platinum Biologics sets a new benchmark in regulatory compliance in biotech.
7 May 2026